Full Breakdown
FDA Expands Approval of Addyi for Women Over 65
12/16/2025, 1:29:31 AM
Expanded Use of Addyi
On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced the expanded approval of Addyi, a medication designed to boost female libido, allowing its use for women over the age of 65 who have gone through menopause. Initially approved in 2015 for premenopausal women experiencing emotional stress related to low sex drive, Addyi has faced scrutiny due to its side effects, which include dizziness and nausea. The drug carries a boxed warning regarding the risks of combining it with alcohol, which can lead to dangerously low blood pressure and fainting.
Background on Female Libido Treatments
Addyi, marketed by Sprout Pharmaceuticals, was anticipated to fill a significant gap in women's health, similar to the impact of Viagra for men in the 1990s. The medical condition known as hypoactive sexual desire disorder has been recognized since the 1990s and is believed to affect a considerable number of American women. However, diagnosing this condition is complex, as various factors—including hormonal changes after menopause—can influence libido. Medical professionals are advised to rule out other potential causes, such as relationship issues and mental health disorders, before prescribing medication.
Official Statements & Responses
Cindy Eckert, CEO of Sprout Pharmaceuticals, stated that the FDA's decision reflects "a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized." The approval follows a lobbying campaign by Sprout and its supporters, including the advocacy group Even the Score, which framed the lack of treatment options for female libido as a women's rights issue.
Criticism & Opposition
Despite the approval, some psychologists and medical professionals argue against the classification of low libido as a medical problem, suggesting that it may not warrant pharmaceutical intervention. The diagnosis of hypoactive sexual desire disorder is not universally accepted, and critics emphasize the need for a broader understanding of women's sexual health beyond medication.
What's Next
The FDA's decision to expand Addyi's use may lead to further discussions about women's health and the treatment of sexual dysfunction. The ongoing debate surrounding the medicalization of low libido and the implications for women's health care continues to evolve as more treatments are considered.
Verbatim Quotes
- “reflects a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized.” — Cindy Eckert, CEO of Sprout Pharmaceuticals
This expansion of Addyi's approval marks a significant moment in the ongoing conversation about women's health and the complexities surrounding sexual desire.
